Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Organic Letters|August 12, 2005
Solid-phase synthesis of N-formylhydroxylamines (reverse/retro-hydroxamates)Steve Price, Susan E OsbournNicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|June 17, 2009
Relationship between physical activity and type of smoking behavior among adolescents and young adults in CyprusMarianna Charilaou, Maria Karekla, Marios Constantinou, et al.Infection Control and Hospital Epidemiology|May 29, 2019
Creating reasonable antibiograms for antibiotic stewardship programs in nursing homes: Analysis of 260 facilities in a large geographic region, 2016-2017Scott K Fridkin, Jacob Pack, Giancarlo Licitra, et al.Bioorganic & Medicinal Chemistry Letters|September 7, 2014
Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479Kirk D Robarge, Wendy Lee, Charles Eigenbrot, et al.Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.Bioorganic & Medicinal Chemistry Letters|November 11, 2006
Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitorsSteve Price, Walter Bordogna, Richard J Bull, et al.Bioorganic & Medicinal Chemistry Letters|March 20, 2010
Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonistsSue Cramp, Hazel J Dyke, Christopher Higgs, et al.Bioorganic & Medicinal Chemistry Letters|November 17, 2006
Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitorsSteve Price, Walter Bordogna, Ruth Braganza, et al.Bioorganic & Medicinal Chemistry Letters|July 23, 2013
Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivityBrian S Safina, Zachary K Sweeney, Jun Li, et al.Journal of Medicinal Chemistry|December 4, 2009
Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sitesIgor Shamovsky, Chris de Graaf, Lisa Alderin, et al.Pageof 2